

August 3, 2006

PTO/SB/08a/b (07-06)
Approved for use through 07/31/2006. OMB 0601-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	Not Yet Assigned 10/597695
		Filing Date	Concurrently Herewith
		First Named Inventor	Akio Nakamura
		Art Unit	NIA- 1614
		Examiner Name	Not Yet Assigned- Spivack
Sheet	1	of	2
Attorney Docket Number		20855/0205125-US0	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA*	US-4,637,229		06-06-1989	Rokos et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/P.S./	BA	WO-84/04041-A1	10-25-1984	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	
	BB	JP-60-501105-A	07-18-1985	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	Corresponds to Citation No. BA
	BC	JP-60-69061-A	04-19-1985	HENNING BERLIN GMBH CHEMIE- UND PHARMAWERK	Corresponds to Citation No. AA

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.989(c)(2)) because that application was filed after June 30, 2003 or is available in the EPO. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Examiners Office that issued the document, by the two-letter code (WFO Standard 37.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WFO Standard 37.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.		T ²
/P.S./	CA	KOICHI NAKAMARU, et al., Effect of mesalazine, an agent for the treatment of idiopathic inflammatory bowel disease, on reactive oxygen metabolites and LTB ₄ formation, <i>Folia Pharmacol. Jpn.</i> , 104, pp. 447-457, 1994.		✓
/P.S./	CB	KOICHI NAKAMARU, et al., Effect of mesalazine microgranules on experimental colitis, <i>Folia Pharmacol. Jpn.</i> , 104, pp. 303-311, 1994.		✓
/P.S./	CC	M. C. M. RUK, et al., Disposition of 5-Aminosalicylic Acid by 5-Aminosalicylic Acid-Delivering Compounds, <i>Scandinavian Journal of Gastroenterology</i> , 23, pp. 107-112, 1988.		
/P.S./	CD	DAVID R. FRIED, Colon-specific drug delivery, <i>Advanced Drug Delivery Reviews</i> , 7, pp. 149-199, 1991.		
	CE	HABUKO HIGAKI, et al., Clinical Studies of Orally Controlled-Release Mesalazine, <i>N.SASA, Japanese Pharmacology & Therapeutics</i> , Vol. 22, Suppl. 10, 1994		✓
	CF	ISTVAN CSIBO, et al., 5-Amino-salicylic-acid-conjugated polymeric microspheres, <i>Megyeri Kemiai Folyarat</i> , 37(4), pp. 143-148, 1991		✓
/P.S./	CG	FERENC SZTARICKAI, et al., Antilucer Effect of the N- and O-β-D-Glucopyranosides of 5-Aminosalicylic Acid, <i>Archiv der Pharmazie An International Journal Pharmaceutical and Chemical Chemistry</i> , 332(9), pp. 321-326, 1999.		
/P.S./	CH	MICHITAKA GOTO, Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs, <i>Journal of Pharmacy and Pharmacology</i> , 53, pp. 1711-1720, 2001.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Phyllis Spivack/	Date Considered	05/23/2008
--------------------	-------------------	-----------------	------------